Marked Increase in Pediatric RSV Hospitalizations Seen Postpandemic
By Lori Solomon HealthDay Reporter
TUESDAY, June 18, 2024 -- Hospital volumes for pediatric respiratory syncytial virus (RSV) rose significantly following the pandemic, along with the need for advanced respiratory support in older children with fewer comorbidities, according to a study published online June 13 in JAMA Network Open.
Zachary A. Winthrop, M.D., from Boston Children’s Hospital, and colleagues analyzed demographics, respiratory support modes, and clinical outcomes of children with RSV infections at tertiary pediatric hospitals (2017 to 2023) using data from 288,816 children aged 5 years and younger treated for RSV at 48 freestanding U.S. children’s hospitals registered in the Pediatric Health Information System.
The researchers found that RSV hospital presentations increased from 39,698 before the COVID-19 pandemic to 94,347 after the pandemic, which was accompanied by an 86.7 percent increase in hospitalizations (50,619 versus 27,114). Compared with prepandemic, in 2022 to 2023, children were older (median age, 11.3 versus 6.8 months) and had fewer comorbidities (17.6 versus 21.8 percent). In 2022 to 2023, there was a 70.1 percent increase in advanced respiratory support (9,094 versus 5,340).
"Although these trends need to be evaluated in subsequent years, this study highlights possible epidemiologic shifts and trends in respiratory support use that may help inform guidelines and expanded age considerations for new RSV vaccines as they become more widely available," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Further Support and Information on COVID-19
Read this next
RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization
TUESDAY, May 13, 2025 -- Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among...
Nirsevimab Effective for Reducing Burden of RSV in Infants
THURSDAY, May 8, 2025 -- Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published...
72 Percent of Infants Immunized Against Respiratory Syncytial Virus
TUESDAY, May 6, 2025 -- In a recent study of a population of infants, published online May 6 in Pediatrics, 72 percent of infants were found to be immunized against respiratory...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.